Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | DRD5 | P21918 | 5/20 | 0.48 |
| ▸ | DRD3 | P35462 | 5/20 | 0.48 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 8/20 | 0.45 |
| ▸ | BRD4 | O60885 | 5/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092656 | 0.87 | MEN1 (0.57) | HDAC1HDAC6RORCHRH3DRD1 | |
| SCHEMBL28805650 | 0.86 | HDAC1 (0.53) | HDAC1HDAC6RORCHRH3DRD1 | |
| SCHEMBL8604886 | 0.84 | HRH3 (0.62) | HDAC1HDAC6RORCHRH3DRD1 | |
| SCHEMBL10490519 | 0.82 | HRH3 (0.52) | HDAC1HDAC6RORCHRH3DRD1 | |
| SCHEMBL8606442 | 0.82 | HDAC1 (0.53) | HDAC1HDAC6RORCHRH3DRD1 | |
| SCHEMBL1428735 | 0.81 | RORC (0.51) | HDAC1HDAC6RORCHRH3DRD1 | |
| SCHEMBL8302626 | 0.81 | HDAC1 (0.54) | HDAC1HDAC6RORCCREBBPBRD4 | |
| SCHEMBL11789019 | 0.81 | ALDH1A1 (0.51) | HDAC1HDAC6RORCHRH3HSD17B10 | |
| SCHEMBL1394587 | 0.80 | RORC (0.50) | HDAC1HDAC6RORCHRH3DRD1 | |
| SCHEMBL14986091 | 0.79 | HRH3 (0.61) | HDAC1HDAC6RORCHRH3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-5750409-A | MARKERS FOR HAPTEN-ANTIBODY-PROTEIN CONJUGATES | BOEHRINGER MANNHEIM GMBH (DE) | 1998-05-12 | — | — | US | disclosed |
| EP-0567622-B1 | NEW PENTACYCLIC COMPOUNDS AND THEIR USE AS ABSORPTION OR FLUORESCENCE DYES | BOEHRINGER MANNHEIM GMBH (DE) | 1996-04-24 | — | — | EP | disclosed |
| WO-1993010189-A1 | NEW PENTACYCLIC COMPOUNDS AND THEIR USE AS ABSORPTION OR FLUORESCENCE DYES | BOEHRINGER MANNHEIM GMBH (DE) | 1993-05-27 | — | — | WO | disclosed |
| EP-0543333-A1 | New pentacyclic compounds and their use as absorption or fluorescence dyestuffs | Roche Diagnostics GmbH (DE) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | HDAC1 593/4885HDAC6 1224/4885RORC 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.